Objectif
Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by:
1. Optimizing local control by introducing novel radiation techniques resulting in redistribution of the radiation dose, creating inhomogeneous dose distribution towards the most active part of the tumour instead of conventional homogenous doses. This redistribution can be performed without increase of toxicity. As recently reported radiation accidents in the US demonstrate, QA is of outmost importance for safe radiation delivery in complex treatments. To assure accurate delivery over time, we will monitor both the patient’s geometry as well as the delivered dose using image guided adaptive plan modifications and 3D in-vivo dosimetric verification.
2. Maximizing the benefit of combined modality treatment
Both cisplatin and Cetuximab in combination with radiotherapy have shown to improve local control and survival but both drugs have severe side effects. As these drugs are not active in all patients, there is a large need to select patients which are sensitive to either drug. For this purpose the uptake of Cetuximab will be estimated by imaging tumour uptake with Zr89 labelled Cetuximab, while cisplatin sensitive tumours can be selected by biomarkers. This part was stopped in May 2014.
This proposal will:
1 optimise efficiency by selecting patients on treatment specific tumour response predictors and tailoring radiation to most active parts of the tumour.
2 improve quality of life by withholding ineffective, toxic treatments and redistribution of dose.
3 decrease community costs by reserving expensive treatments for those who will benefit.
This will be studied in randomized phase II clinical trials in top European institutes, followed by phase III trials outside this proposal.
Champ scientifique
Appel à propositions
FP7-HEALTH-2010-two-stage
Voir d’autres projets de cet appel
Régime de financement
CP-FP - Small or medium-scale focused research projectCoordinateur
1066 CX Amsterdam
Pays-Bas
Voir sur la carte
Participants (14)
17177 Stockholm
Voir sur la carte
1000 Bruxelles / Brussel
Voir sur la carte
6229 ET Maastricht
Voir sur la carte
08007 Barcelona
Voir sur la carte
75654 Paris
Voir sur la carte
6229ET Maastricht
Voir sur la carte
111 34 Stockholm
Voir sur la carte
M20 4BX Manchester
Voir sur la carte
94805 Villejuif
Voir sur la carte
1066CX AMSTERDAM
Voir sur la carte
104 22 Stockholm
Voir sur la carte
3015 GD Rotterdam
Voir sur la carte
3584 CX Utrecht
Voir sur la carte
9713 GZ Groningen
Voir sur la carte